argenx SE Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis - Call Transcript
Good morning, everyone, and welcome to the argenx ADAPT Phase III trial top line results conference call. (Operator Instructions)
I would now like to introduce Beth DelGiacco, Vice President of Investor Relations at argenx. Please go ahead.
Thank you, and good morning to everyone on the call. Earlier today, we issued a press release summarizing our positive top line Phase III ADAPT trial results. The press release and the presentation for today's webcast can be found on our website.
On the call today are Tim Van Hauwermeiren, our Chief Executive Officer; and Wim Parys, our Chief Medical Officer. Keith Woods, our Chief Operating Officer, will be available for the Q&A session following prepared remarks.
Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory time lines, the potential success of our product candidates, financial projections
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
